Skip to main content
Premium Trial:

Request an Annual Quote

CytRx Closes Acquisition of Global Genomics

NEW YORK, July 18 - CytRx said today it has completed its acquisition of Global Genomics Capital, and has named Steven Kriegsman CEO of the new company.

 

Terms of the deal, originally announced in February, call for CytRx to acquire all outstanding shares of Global Genomics, a private holding company. In return, CytRx will issue almost 10 million shares of common stock. The company also said it will change its name to Global Genomics.

    

Global Genomics, based in Los Angeles, owns 40 percent of Blizzard Genomics and five percent in Psynomics.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.